Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma Interventions: Drug: Rituximab; Drug: Gemcitabine; Drug: Dexamethasone; Drug: Cisplatin; Drug: PD-1 monoclonal antibody Sponsors: Ou Bai, MD/PHD; Second Hospital of Jilin University; China-Japan Union Hospital, Jilin University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chemotherapy | China Health | Dexamethasone | Hospitals | Lymphoma | Research | Rituxan | T-cell Lymphoma